Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study

Published:2013-11-19 Issue:5 Volume:61 Page:833-839
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Bagatell Rochelle¹,Norris Robin²,Ingle Ashish M.³,Ahern Charlotte⁴,Voss Stephan⁵,Fox Elizabeth¹,Little Anthony R.¹,Weigel Brenda J.⁶,Adamson Peter C.¹,Blaney Susan⁴

Affiliation:

1. The Children's Hospital of Philadelphia; Philadelphia Pennsylvania

2. Rainbow Babies and Children's Hospital; Cleveland Ohio

3. Children's Oncology Group Statistics and Data Center; Arcadia California

4. Texas Children's Cancer Center/Baylor College of Medicine; Houston Texas

5. Dana-Farber Cancer Institute/Children's Hospital Boston; Boston Massachusetts

6. University of Minnesota; Minneapolis Minnesota

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference32 articles.

1. Growing roles for the mTOR pathway;Sarbassov;Curr Opin Cell Biol,2005

2. mTOR signaling and drug development in cancer;Dancey;Nat Rev Clin Oncol,2010

3. Molecular mechanisms of mTOR-mediated translational control;Ma;Nat Rev Mol Cell Biol,2009

4. Regulation of cap-dependent translation by eIF4E inhibitory proteins;Richter;Nature,2005

5. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies;Barrett;Paediatr Drugs,2012

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615);European Journal of Cancer;2024-09

2. Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: A report from the National Ewing Sarcoma Tumor Board;Cancer;2024-08-25

3. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer;European Journal of Cancer;2024-08

4. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial;The Lancet Oncology;2024-07

5. The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution;eClinicalMedicine;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3